PA R I S R E G I O N

BIOCLUSTER
THE ALCHEMY OF SUCCESS
Paris Region is at the forefront of the Life Sciences
in Europe (Ernst & Young report, 2004), and what
better testimony than the Paris Region BioCluster, a
convergence of leading pharmaceutical companies,
medical device manufacturers, biotech companies,
services, hospitals, research centers and academic
institutions, all located in the region. The willingness
of players in both the public and private sectors to join
forces to energize and accelerate the development of
BioCluster promises that the Paris Region region can
look forward to a sustainable growth.
BioTeam® Paris Region supports and coordinates the
BioCluster project, promoting international visibility of
BioCluster and providing companies with resources
and services to set up in the Paris region.
> Paris Region BioCluster:
gateway to innovation
Paris Region BioCluster counts some 830 pharma-
ceutical companies, medical device manufacturers and
biotech firms employing more than 46,600 people.
These enterprises are always on the lookout for part-
nerships and collaborations to promote discovery, inno-
vation, production and commercialization.
Pharmaceutical companies:
Paris Region, No 1 in Europe
Over 320 companies with a workforce of 32,200.
Nineteen of the twenty worldwide leaders are located
in Paris Region, including GlaxoSmithKline, Novartis,
Pfizer, Sanofi-Aventis, to name a few. A good many of
them have entered into contractual collaborations
with biotech companies (Lilly and Cerep, Sanofi-
Aventis and Immuno-Designed Molecules are some
examples).
Medical device manufacturers:
Paris Region, No 2 in Europe
360 companies employing more than 10,400 people. World
leaders like B Braun Medical, General Electrics Medical
Systems, Guerbet and Siemens are present in the region.
Biotech companies:
Paris Region, No 2 in Europe
150 companies, or about half of the nationwide total,
employing some 4,000 people. Amgen, Biogen Idec,
Genzyme and Serono are just some of the world lead-
ers located in the region, alongside French biotech com-
panies like Bioalliance, BioMedical Diagnostic, Cerep,
Chemunex, Diatos, Exonhit Therapeutics, Hybrigenics,
Immuno-Designed Molecules, Nautilus and Urogene.
70% of venture capital investments in France are slated
for biotech companies in Paris Region, making for a
dynamic sector and underscoring the confidence in
this melting pot of competencies. To further promote
research and innovation, the Paris Region Regional
Council has decided to double its R&D expenditures to
5% of its total budget. A large part will be used to accel-
erate the development of the Paris Region BioCluster.
> Paris Region Research:
a tradition of excellence
dating back to Pasteur
Paris Region ranks as the No 1 science and technology
region in the 25-member European Union, accounting
for 7.5% of European domestic R&D expenditures and
hosting some 11,800 researchers, 4,400 of whom work
in industry. The human and financial resources it has to
offer outweigh those of other countries such as the
Netherlands or Spain.
> Paris Region
key figures
Population: 11 million
5.4 million jobs
Leading industrial region in France
providing 14.9% of industrial employment
nationwide
GDP: 430 billion
617,000 businesses
17 universities
20,000 engineers trained every year
68,000 researchers
2,500 private and public laboratories

> Paris Region

BioCluster
880 companies and 57,000 direct jobs
(pharmaceutical groups, medical device
manufacturers, biotech companies,
CROs, academic research)
11,800 researchers
of which 7,400 in academic research
600 health care establishments
80,000 beds and 42,000 practitioners
9 universities and more than 20 higher
education institutions in the Life Sciences

> Number of companies

in the three main European
clusters for the year 2004

900 Medical device

800 manufacturers

700
600
500 Pharmaceutical
400 companies

300 Biotech
200 companies

100
100

Paris Region Greater London Bavaria

* Amadeus data for pharmacy and medical device,

Paris Region Development Agency, London First and Lifescience Bavaria
data for biotechnology
Paris Region places first among all European regions
(Ernst & Young report) in terms of the number of pub-
lications in fundamental biology, medical research,
applied biology and ecology - further proof of its inter-
national reputation. Paris Region is also the European
leader, ahead of London, in pharma/biotech patent
applications.
Oncology, cardiology, gerontology, infectious diseases,
neurosciences, gene and cell therapy, genomics/post-
genomics are just some of the internationally recog-
nized competencies. Today, the Regional Council is
backing a number of projects being developed in these
fields, such as Canceropole Paris Region (oncology),
the Brain and Spinal Cord Institute and Neurospin (neu-
rosciences and degenerative diseases).
The Regional Council is also boosting funding for pres-
tigious centers of research such as the Pasteur Insti-
tute (infectious, parasitic and nosocomial diseases)
and the Evry Genopole (biotechnology).
Academic research collaborations with foreign insti-
tutions are numerous, and there is a strong participa-
tion in international networks such as The European
Vascular Genomics Network, coordinated by the Paris
Region researcher Dr. Alain Tedgui from INSERM, and
COBRA (to fight against bacterial antibiotic resistance)
directed by Prof. Laurent Gutmann from INSERM.
Paris Paris Region derives its international renown
from the sheer numbers of Life Science institutions
including, among others, CNRS, INSERM, Institut
Pasteur, Institut Curie, Institut Gustave Roussy, CEA,
Evry Genopole, Hôpital Saint-Louis, Hôpital
Pitié-Salpêtrière, Hôpital Henri Mondor, Université
Pierre et Marie Curie and Ecole Normale Supérieure.
Prestigious centers of research, these different
institutions also act as business incubators. Indeed,
from 1999 to 2003, the CNRS in Paris Region alone
seeded 25 new companies.
Two ambitious projects illustrate the region’s poten-
tial for technological innovation. The first is the
Synchrotron Soleil, under construction on the Saclay
plateau, which will serve as a center of cutting-edge
scientific research. When it opens in 2006, its 300
researchers and technicians will use their know-how in
physics, materials sciences, biology and medicine,
chemistry, environmental sciences and geophysics to
push back the boundaries of their fields.
ImaGene, a multidisciplinary imaging platform for the
development and validation of preclinical and clinical
cell and gene therapy approaches, is the fruit of a joint
collaboration between INSERM and the CEA. It will be
located at the CEA facilities in Fontenay-aux-Roses.
The private research sector in Paris Region can only be
described as dynamic and entrepreneurial. Paris Region
plays host to the world leaders in pharmaceuticals
(Sanofi-Aventis, GlaxoSmithkline), medical device man-
ufacturers (General Electrics Medical Systems) and
biotechnology companies (Immuno-Designed Molecules,
Serono). Its enormous workforce and high level of R&D
budgeting for private research make Paris Region a driv-
ing force for innovation in the Life Sciences.
Partnerships between private industry and public
research are on the rise. A prime example is Taxotere,
an anticancer blockbuster at Sanofi-Aventis that was
discovered by a CNRS group in Paris Region.
As far as clinical research is concerned, Paris Region
boasts more than 600 health care establishments with
80,000 beds, 42,000 practitioners and a recruitment
potential of 11.5 million inhabitants. AP-HP (Assitance
Publique-Hôpitaux de Paris) is the largest hospital net-
work in Europe with 45 hospital centers and 25,000
beds, and the leader in clinical trial research in France.
CROs (Contract Research Organizations), which man-
age clinical trials, have a considerable presence in
Paris Region, and the 10 world leaders including MDS
Pharma Services, PPD, and Quintiles are located here.
> Educational institutions:
generating a steady
stream of highly qualified
professionals
Nine universities in the region offer a complete
Medical and Life Sciences curriculum, with a
combined student body of 45,000 in the Life Sciences,
34,000 in Medicine (in collaboration with 12 teaching
hospitals), 5,400 in Pharmacy and 2,450 in Dentistry.
Specialized masterís degrees provide additional
qualifications in fields such as bioinformatics,
biostatistics, law, health economics and many more,
thanks to partnerships between universities and
research institutions (among others: AP-HP, CEA,
CNRS, INSERM)
Graduate schools grant more than 460 Ph.D.s every
year in a variety of fields including biochemistry,
molecular biology, oncology, and biomaterials.
Some 20 higher education institutions offer advanced
training geared to different sectors, from engineers:
Institut Supérieur des Biosciences, Institut Supérieur
Biotech de Paris, Ecole de Biologie Industrielle, Ecole
Polytechnique, Ecole Supérieure de Physique et de
Chimie Industrielles, to managers: ESA BIO, Institut
Supérieur de Technologie et Management, to name a
few.
Thanks to the quality and complementarity of educa-
tional institutions in Paris Region, companies can tap
into a huge reservoir of highly qualified professionals
to meet their needs. Upper level executive and profes-
sional positions account for one-fourth of the working
population. The appeal of the Paris region is also an
undeniable asset that helps companies attract top-
flight professionals from all over the world.
After all is said and done, Paris Region BioCluster conjures up a
winning mix of industry, biotech, academic research, hospitals,
business environment and infrastructures. And on top of all that,
the preferred meeting venue of European investors offers an
unequalled quality of life recognized the world over.
> Paris Region BioCluster:
a business catalyst
Paris Region also plays host to the partners of Bio-
Cluster businesses, including manufacturers (Delpharm,
LCO Santé…), pharmaceuticals distributors (CERP
Rouen, OCP Répartition…), medical visitor services
(Cider Santé), and strategy, marketing, regulatory
affairs and industrial property consultants, together
with two regional centers for innovation and technology
transfer (CRITT Chimie and Bio CRITT). Last but not
least, the fact that all the governmental authorities
(ministries, AFSSAPS, GEMED…) are present in the
region is an advantage that cannot be overlooked.
Access to financing and to specialized real estate is
particularly easy in Paris Region. The region counts
90% of all venture capital firms specialized in the Life
Sciences present in France, in addition to regional seed-
stage (CapDécisif) and venture capital funds (Paris
Region Développement).
As the European leader in business real estate, Paris
Region can offer facilities specially dedicated to the Life
Sciences. With 10 specialized sites, in 2005 the compa-
nies in BioCluster can choose from more than 110,000
square meters of industrial/office space, at highly com-
petitive prices (€ 200-500 per sq. m. before charges). In
addition historic industrial sites can be found within a
20 km radius of Paris. An additional 34,000 sq. m. of
space will become available between 2005 and 2006.
With two international airports and a high-speed train
system (TGV), Paris is less than an hour and a half from
London, Frankfurt or Brussels. Easy access also makes
Paris Region a top choice for meetings and conven-
tions such as Eurobiotech, Médec, Pharmagora, which
bring together European-wide decision-makers in
industry, research and financing.
> Bioteam® Paris Region
An umbrella organization created at the initiative
of Paris Region Development Agency,
Essonne Development and Paris Development,
Bioteam® Paris Region brings together and
creates synergies between the key players
in the Life Sciences sector in Paris Region:
local governments, business, academic research,
hospitals as well as a vast network of competencies
and resources including business incubators, CROs,
intellectual property expertise, consulting
and supporting services.
Bioteam® Paris Region also counts
the Essonne Chamber of Commerce and Industry
and the Val-de-Marne Development Agency
among its partners.
Bioteam® Paris Region implements and coordinates
promotional activities to give Paris Region BioCluster
international visibility and recognition.
www.bioteam-parisregion.org
contactbioteam@paris-region.com
> PDRA
Paris Region Development Agency (PRDA)
has four main missions:
Prospecting
bio – entrepreneurs, particularly world –
wide companies, that want to set up in Paris Region,
welcoming and helping them find all the resources
they need to consolidate their presence in the region.
Promoting
the region’s international image as an economic
and technological hub.
Sharing
strategic economic information with players
involved in developing the local economy.
Participating
in the redevelopment of transitional areas
and sites.
Paris Ile-de-France
Agence Régionale de Développement
3, rue des Saussaies, 75008 Paris, France
Tél : 33 (1) 58 18 69 00
www.paris-region.com